ORALLY ADMINISTERED SP 303 FOR TREATMENT OF DIARRHEA IN AIDS PATIENTS

口服 SP 303 用于治疗艾滋病患者的腹泻

• 批准号: 6304511
• 负责人: Paul R Skolnik
• 金额: $ 4.27万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304511
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; clinical research; combination chemotherapy; comorbidity; diarrhea; drug adverse effect; drug resistance; drug screening /evaluation; gene mutation; human subject; human therapy evaluation; oral administration; therapy compliance; virus load

Diarrhea is a substantial problem for many HIV-infected persons. The causes of diarrhea in this patient group are many; they include problems with absorption, infections that may cause diarrhea, and side effects of drug that are needed to treat HIV infection or prevent opportunistic illnesses. Methods of decreasing drugs side effects are especially important now that highly active antiretroviral therapy is available that decreases viral load and increases survival. Taking these drugs without interruption is important to decrease the chances of mutations in the HIV genome that might result in drug resistance. SP-303 is an investigational agent that has been effective in decreasing diarrhea in other patient groups. This study will determine the safety and efficacy of this drug for the treatment of diarrhea in patients with AIDS.

腹泻对许多艾滋病毒感染者来说是一个严重的问题。这组患者腹泻的原因有很多，包括吸收问题、可能导致腹泻的感染以及治疗艾滋病毒感染或预防机会性疾病所需的药物的副作用。随着高效抗逆转录病毒疗法的出现，减少药物副作用的方法变得尤为重要，这种疗法可以减少病毒载量，提高存活率。不间断服用这些药物对于减少可能导致耐药性的艾滋病毒基因组突变的机会很重要。SP-303是一种研究药物，在减少其他患者组的腹泻方面一直很有效。这项研究将确定该药物治疗艾滋病患者腹泻的安全性和有效性。